Developing Novel Therapies for Neurodegenerative Disorders
Siragen Pharmaceuticals is a biotechnology company focused on novel approaches to treat aging disorders of the brain.
What We Do
Siragen Pharmaceuticals is a drug discovery and development company, focused on novel approaches to treat aging disorders of the brain such as Alzheimer’s and Parkinson’s diseases.
Aging population worldwide will boom in next 20 years. Neurodegenerative disorders (Alzheimer’s, Parkinson’s disease, ALS, mixed dementias) are present in 1 in 5 patients over 65 years old and actuarial studies have projected an exponential financial burden for the next generations.
Current therapies are ineffective in treating the underlying cause, or even in stopping the progression of neurodegenerative disorders. Experimental treatments targeting advanced and static end-stage pathology in Alzheimer’s disease (amyloid β / senile plaques and Tau/neurofibrillary tangles) failed repeatedly in large clinical trials. A novel conceptual framework is needed to change these outcomes. This is where Siragen makes a difference.
Siragen drug discovery efforts focuses on cellular mechanisms that protect neurons from aging disruption at the synapse, the basic communication structures of neurons. These processes maintain the functional balance of central neural circuits and health of synaptic connectivity. This delicate balance is lost in aging neurons and leads to neurodegenerative changes underlying early clinical memory impairment.
We hypothesized this imbalance to be a prime factor precipitating the clinical transition from normal state to early onset and mild cognitive impairments, precursors to late stage dementia and neurodegeneration.
Siragen has identified key components of this system becoming disrupted at the early onset of aging changes. Siragen’s solution is to target this pathway by inhibiting a protein central to this network. Following preclinical studies, Siragen’s molecules successfully corrected disease markers of immuno-inflammation, restored memory deficits and synaptic function in Alzheimer’s disease animal models, which validates Siragen’s hypothesis. This represents a paradigm shift in the treatment approaches to neurodegenerative disorders.
Siragen’s goal is to bring these novel treatments to clinical trials, staying at the forefront of therapies of neurodegenerative disorders.